WO2000006180A1 - Composicion para la estimulacion de la sintesis del pigmento melanico y procedimiento para su obtencion - Google Patents
Composicion para la estimulacion de la sintesis del pigmento melanico y procedimiento para su obtencion Download PDFInfo
- Publication number
- WO2000006180A1 WO2000006180A1 PCT/CU1999/000003 CU9900003W WO0006180A1 WO 2000006180 A1 WO2000006180 A1 WO 2000006180A1 CU 9900003 W CU9900003 W CU 9900003W WO 0006180 A1 WO0006180 A1 WO 0006180A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- composition
- skin
- synthesis
- product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
Definitions
- the present invention relates to the branch of Medicine
- Vitiligo or leucoderma is a disease among the oldest known to civilization that is characterized by the loss of melanin pigment producing cells in the skin. This disease affects approximately 1% of the world population, without distinguishing age, sex, or race. It is of unknown etiology and without a defined therapy so far, manifesting itself by a gradual depigmentation of the skin of patients subjected to situations of extreme nervous tension, which adversely affects their psyche and social behavior once their external symptoms begin, under the aspect of white skin areas surrounded by a halo of hyperpigmentation, manifesting primarily in the face, trunk or joint regions.
- psoralens are not free of toxic side effects, being able to cause dermatitis and skin necrosis when applied topically. In addition, its effect is slow and reversible in most cases when the medication is discontinued. On the other hand, these substances present difficulties for their application, which requires the gradual increase of the patient's daily exposure time to ultraviolet radiation, sometimes causing severe toxic reactions such as burns due to topical administration or liver failure, digestive, renal disorders and nervous with its oral administration.
- Melagenina Lotion® is a 50% alcoholic extract of human placenta, which is obtained from healthy pregnant women in aseptic conditions after normal deliveries. This extract contains a lipopro protein of molecular weight between 1500-4000 Daltons, which constitutes its active substance. This substance stimulates the reproduction of melanocytes and the synthesis of the melanin pigment, also accelerating the oxidation of the amino acid L-Dopa in the presence of sunlight, which favors its transformation into melanin after internal chemical processes.
- Melagenina Lotion® has been used successfully so far for the treatment of vitiligo. According to clinical trials, its use has achieved remarkable effectiveness in all patients where it has been applied (Miyares Cao C, Taboas M. and López H. "Preliminary report on the use of human placental extract in the therapy of Vitiligo ". Cuban Journal of Pharmacy 10
- Melagenina Lotion® although it lacks harmful side effects, is a product that has to be used in three daily applications with an interval between them of 8 hours, and accompanied by solar or infrared exposure in one of the applications, which makes compliance difficult of treatment by a large part of the patients.
- the novelty of the present invention consists of a new composition containing the same active ingredient of Melagenin Lotion®, in this case an alfalipoproin obtained from human placental cotyledons, by processing these active ingredient of Melagenin Lotion®, in this case an alfalipoproin obtained from human placental cotyledons, by processing these active ingredient of Melagenin Lotion®, in this case an alfalipoproin obtained from human placental cotyledons, by processing these
- SUBSTITUTE SHEET (RULE 26) with organic solvents, and its subsequent redisolution in an ethanol solution with calcium chloride, which allows a product to be obtained that shows a synergistic effect between both components in its pigmenting effect, thus reducing the number of applications of said product of 1 every 8 hours by patients, at 1 every 24 hours, also eliminating the need to expose the patient to solar or infrared radiation after one of the applications.
- the new product thus obtained hereinafter referred to as "Melagenin Plus", can be used by a single daily application, which constitutes the current practice in world therapeutics.
- Said product stimulates the synthesis of the melanin skin pigment and the reproduction of the melanocytes as evidenced by the pharmacological tests to which it was subjected, totally lacking severe side reactions as demonstrated by the toxicological, teratological and clinical tests performed. It is easy to obtain and apply, and the repigmentation effect begins quickly (15 to 20 days) after starting treatment, being irreversible when discontinuing the application of the product.
- the color acquired by the skin where it is applied is identical to the areas of the patient's normal skin, which in turn do not increase the intensity of their coloration later.
- the raw material from which the active substance of the product is extracted is a human tissue, there are no immune reactions to fear, there are no contraindications regarding age, sex or race for its use. Obtaining the active substance of the Melagenin composition
- SUBSTITUTE SHEET (RULE 26) filtered this macerated through thick gauze, allowing it to stand for 24 hours.
- the supernatant was determined its pigmenting activity, which was positive 20 to 50 days after being used topically on Balb / C 57 BL 6 mouse ears.
- the precipitate was washed again 2 to 10 times with 100 to 500 ml of acetone, dried under vacuum and at room temperature.
- the product was redissolved in 90 to 96 ° alcohol containing 0.2 to 4.0 mg / ml calcium chloride.
- Two protein peaks were obtained, the first from 100 to 300 ⁇ g / ml and the second from 20 to 150 ⁇ g / ml.
- the pigmenting activity was positive for the second peak, appearing 10 or 20 days after the lyophilized mixture was used topically in the curl.
- SUBSTITUTE SHEET (RULE 26) The lyophilized mixtures of both protein peaks were electrophoresed with polyacrylamide gel and agarose, the first being stained with a protein dye (black amido) and the second to detect lipids (sweat). In the protein electrophoresis a small colored band was observed followed by an uncoloured one, both migrated little; a well visible band was also noted in the albumin region. In lipid electrophoresis, only one band was observed in the region where alfalipoproproteins migrate.
- D Melagenin Lotion with addition of calcium chloride in a concentration of 1 mg / ml (Melagenin Plus) 70% alcohol, 70% alcoholic solution with calcium chloride, 1 mg / ml, as well as Melagenin Lotion® and Melagenina Plus were applied by rubbing them with the fingers of the operator on the ears of the animals.
- SUBSTITUTE SHEET (RULE 26) which allows, by microscopic observation, the melanocyte count per mm 2 in said histological structure.
- SUBSTITUTE SHEET (RULE 26) black mice treated with Melagenin Lotion® and Melagenin Plus, with respect to the alcohol treated and untreated groups. The increase in the number of melanocytes was greater in animals treated with Melagenin Plus. Other differences found were:
- Melagenin Lotion® and Melagenin Plus are applied interchangeably in biological tests, it was observed that in the case of Melagenin Plus the pigmenting effect on male curly nipples is visible in only 13 days, while with Melagenin Lotion® this occurs at 18 days. Similarly, in the tail of black mice, a higher concentration of melanin is observed when using Melagenin Plus when the cuts are treated by the histochemical method, where a greater increase in melanocytes in the basal region of the epidermis was observed. Studies of skin irritation of animals.
- Melagenina Plus was applied to a group of animals in an area of 42 cm 2 with a dose of 20 mg / cm 2 and in that same animal
- Lotion® 50% Alcoholic Placenta Human Extract
- applying it topically by rubbing with the fingers on skin areas depigmented by the disease, on three daily occasions with 8-hour intervals (6.00 am, 2.00 pm and 10.00 pm).
- the treated areas had to be exposed to infrared light lamps of 250 watts intensity, placed 40 cm away, for 15 minutes.
- the drug application should be repeated every 5 minutes in that time interval.
- the members of group II would use Melagenina Plus (Alcoholic Extract of Placenta Humana at " 50% containing Calcium Chloride) applying it in the same way 'but on a single daily occasion, without exposure to infrared radiation and with intervals of 24 hours The participants in the trial had to remain before their start without specific treatment.
- Melagenina Plus Alcoholic Extract of Placenta Humana at " 50% containing Calcium Chloride
- the patients object of the experience were evaluated monthly for a period of 6 months, set to compare in both groups the degree of repigmentation obtained with each product as well as the occurrence of side reactions.
- Biopsies of depigmented skin areas were performed at the beginning and end of the experience in 5 patients from each group selected
- the histological technique of L-Dopa oxidase was used to identify the melanocytes in them.
- Tables II, III, IV and V The results obtained through said clinical trial are summarized in Tables II, III, IV and V., in which the number of their medical history for identification, age, sex, race have been considered as patient data. and the years they have been suffering from the disease. Among the parameters that have been evaluated are the% of depigmentation at the beginning and at the end of the treatment, the% of pigmentation reached and the bottles of the drug consumed during said treatment. Likewise, the analyzed areas corresponding to each of said treated patients (face, neck, trunk, limbs or genitals) are shown in the table relative to each type of treatment.
- Figure 1 shows the melanocytopoietic action obtained by a black mouse ear test, using groups of
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT99934451T ATE284699T1 (de) | 1998-07-28 | 1999-07-28 | Zusammensetzung zur stimulierung der melaninpigment-synthese und verfahren zu deren herstellung |
EP99934451A EP1101494B1 (en) | 1998-07-28 | 1999-07-28 | Composition for stimulating the synthesis of the melanic pigment and procedure to obtain it |
JP2000562034A JP2002521453A (ja) | 1998-07-28 | 1999-07-28 | メラニン色素の合成を刺激する組成物およびその製造方法 |
UA2001010624A UA63015C2 (en) | 1998-07-28 | 1999-07-28 | Composition for stimulating synthesis of melanic pigment, method for its production and method for treating vitiligo |
MXPA01001014A MXPA01001014A (es) | 1998-07-28 | 1999-07-28 | Composicion para la estimulacion de la sintesis del pigmento melanico y procedimiento para su obtencion. |
HU0103274A HUP0103274A2 (hu) | 1998-07-28 | 1999-07-28 | A melanin pigment szintézisét stimuláló készítmény és eljárás előállítására |
CA002336526A CA2336526A1 (en) | 1998-07-28 | 1999-07-28 | Composition for stimulating the synthesis of the melanic pigment and process for obtaining it |
US09/744,633 US6660305B1 (en) | 1998-07-28 | 1999-07-28 | Composition for stimulating the synthesis of the melanic pigment and process for obtaining it |
BR9913345-8A BR9913345A (pt) | 1998-07-28 | 1999-07-28 | Composição para a estimulação da sìntese do pigmento melânico e procedimetno para a sua obtenção |
DE69922662T DE69922662D1 (de) | 1998-07-28 | 1999-07-28 | Zusammensetzung zur stimulierung der melaninpigment-synthese und verfahren zu deren herstellung |
BG105208A BG105208A (en) | 1998-07-28 | 2001-01-31 | Composition for stimulating the synthesis of the melanic pigment and process for obtaining it |
HK01106963A HK1037520A1 (en) | 1998-07-28 | 2001-10-04 | Composition for stimulating the synthesis of the melanic pigment and procedure to obtain it |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU110/98 | 1998-07-28 | ||
CU1998110A CU22695A1 (es) | 1998-07-28 | 1998-07-28 | Formulación para la estimulación de la síntesis del pigmento melánico |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000006180A1 true WO2000006180A1 (es) | 2000-02-10 |
Family
ID=5459380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU1999/000003 WO2000006180A1 (es) | 1998-07-28 | 1999-07-28 | Composicion para la estimulacion de la sintesis del pigmento melanico y procedimiento para su obtencion |
Country Status (17)
Country | Link |
---|---|
US (1) | US6660305B1 (es) |
EP (1) | EP1101494B1 (es) |
JP (1) | JP2002521453A (es) |
CN (1) | CN1187059C (es) |
AR (1) | AR029307A1 (es) |
AT (1) | ATE284699T1 (es) |
BG (1) | BG105208A (es) |
BR (1) | BR9913345A (es) |
CA (1) | CA2336526A1 (es) |
CU (1) | CU22695A1 (es) |
DE (1) | DE69922662D1 (es) |
HK (1) | HK1037520A1 (es) |
HU (1) | HUP0103274A2 (es) |
MX (1) | MXPA01001014A (es) |
RU (1) | RU2225716C2 (es) |
UA (1) | UA63015C2 (es) |
WO (1) | WO2000006180A1 (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011676A1 (es) * | 2003-08-05 | 2005-02-10 | Centro De Histoterapia Placentaria | Composición para el tratamiento del vitíligo |
WO2010138024A2 (ru) * | 2009-05-29 | 2010-12-02 | Общество С Ограниченной Ответственностью "Медицинский Исследовательский Центр "Иммункулус" | Средство для защиты клеток мозга |
US10597831B2 (en) | 2016-05-10 | 2020-03-24 | Rkm | Rolling device, in particular for placing bulk materials on the ground |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505580A (ja) * | 2006-10-13 | 2010-02-25 | リライアンス ライフ サイエンシーズ ピーヴィーティー. リミテッド | 生体高分子上での培養メラニン細胞 |
EA013133B1 (ru) * | 2008-12-26 | 2010-02-26 | Некоммерческое Учреждение "Научно-Исследовательский Институт Цитохимии И Молекулярной Фармакологии" | Композиция аминокислот подъязычного применения для повышения репигментации кожного покрова при витилиго и способ ее применения |
CN102266586B (zh) * | 2011-06-28 | 2013-12-04 | 江苏省人民医院 | 白癜风黑素细胞移植涂布载体系统的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2537585A1 (fr) * | 1982-12-10 | 1984-06-15 | Cubana Export Import | Procede et produit pour stimuler la synthese du pigment melanique de la peau, notamment pour le traitement du vitiligo, et procede de preparation de ce produit |
US4507277A (en) * | 1983-04-08 | 1985-03-26 | Empresa Cubana Importadora Y Exportadora De Productos Medicos | Composition and method for stimulating the synthesis of the melanotic pigment of the skin |
EP0839535A1 (en) * | 1996-10-17 | 1998-05-06 | Council Of Scientific And Industrial Research | An extract from human placenta containing glycosphingolipids and endothelin-like constituent peptides useful for the treatment of vitiligo |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451358B2 (en) * | 1999-12-29 | 2002-09-17 | Mileuna, Inc. | Composition and method for the treatment of vitiligo |
-
1998
- 1998-07-28 CU CU1998110A patent/CU22695A1/es unknown
-
1999
- 1999-07-27 AR ARP990103684A patent/AR029307A1/es unknown
- 1999-07-28 UA UA2001010624A patent/UA63015C2/uk unknown
- 1999-07-28 BR BR9913345-8A patent/BR9913345A/pt not_active IP Right Cessation
- 1999-07-28 RU RU2001105539/15A patent/RU2225716C2/ru not_active IP Right Cessation
- 1999-07-28 CA CA002336526A patent/CA2336526A1/en not_active Abandoned
- 1999-07-28 DE DE69922662T patent/DE69922662D1/de not_active Expired - Lifetime
- 1999-07-28 US US09/744,633 patent/US6660305B1/en not_active Expired - Lifetime
- 1999-07-28 AT AT99934451T patent/ATE284699T1/de not_active IP Right Cessation
- 1999-07-28 MX MXPA01001014A patent/MXPA01001014A/es active IP Right Grant
- 1999-07-28 JP JP2000562034A patent/JP2002521453A/ja active Pending
- 1999-07-28 WO PCT/CU1999/000003 patent/WO2000006180A1/es active IP Right Grant
- 1999-07-28 HU HU0103274A patent/HUP0103274A2/hu unknown
- 1999-07-28 EP EP99934451A patent/EP1101494B1/en not_active Expired - Lifetime
- 1999-07-28 CN CNB99810745XA patent/CN1187059C/zh not_active Expired - Fee Related
-
2001
- 2001-01-31 BG BG105208A patent/BG105208A/xx unknown
- 2001-10-04 HK HK01106963A patent/HK1037520A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2537585A1 (fr) * | 1982-12-10 | 1984-06-15 | Cubana Export Import | Procede et produit pour stimuler la synthese du pigment melanique de la peau, notamment pour le traitement du vitiligo, et procede de preparation de ce produit |
US4507277A (en) * | 1983-04-08 | 1985-03-26 | Empresa Cubana Importadora Y Exportadora De Productos Medicos | Composition and method for stimulating the synthesis of the melanotic pigment of the skin |
EP0839535A1 (en) * | 1996-10-17 | 1998-05-06 | Council Of Scientific And Industrial Research | An extract from human placenta containing glycosphingolipids and endothelin-like constituent peptides useful for the treatment of vitiligo |
Non-Patent Citations (3)
Title |
---|
C. J. CARSBERG ET AL.: "Intracellular calcium modulates the responses...", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 9, no. 3, May 1995 (1995-05-01), pages 157 - 164, XP002122299 * |
JIMBOW K.: "Vitiligo. Therapeutic advances.", DERMATOLOGIC CLINICS, vol. 16, no. 2, April 1998 (1998-04-01), pages 399 - 407, XP002122297 * |
K. U. SCHALLREUTER ET AL.: "Treatment of vitiligo with a topical application of...", DERMATOLOGY, vol. 190, no. 3, 1995, pages 223 - 229, XP002122298 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011676A1 (es) * | 2003-08-05 | 2005-02-10 | Centro De Histoterapia Placentaria | Composición para el tratamiento del vitíligo |
WO2010138024A2 (ru) * | 2009-05-29 | 2010-12-02 | Общество С Ограниченной Ответственностью "Медицинский Исследовательский Центр "Иммункулус" | Средство для защиты клеток мозга |
WO2010138024A3 (ru) * | 2009-05-29 | 2011-02-10 | Общество С Ограниченной Ответственностью "Медицинский Исследовательский Центр "Иммункулус" | Средство для защиты клеток мозга |
US10597831B2 (en) | 2016-05-10 | 2020-03-24 | Rkm | Rolling device, in particular for placing bulk materials on the ground |
Also Published As
Publication number | Publication date |
---|---|
EP1101494A1 (en) | 2001-05-23 |
HK1037520A1 (en) | 2002-02-15 |
BG105208A (en) | 2001-07-31 |
MXPA01001014A (es) | 2002-06-04 |
CU22695A1 (es) | 2001-07-31 |
AR029307A1 (es) | 2003-06-25 |
UA63015C2 (en) | 2004-01-15 |
JP2002521453A (ja) | 2002-07-16 |
EP1101494B1 (en) | 2004-12-15 |
BR9913345A (pt) | 2001-10-16 |
CA2336526A1 (en) | 2000-02-10 |
ATE284699T1 (de) | 2005-01-15 |
DE69922662D1 (de) | 2005-01-20 |
HUP0103274A2 (hu) | 2002-01-28 |
RU2225716C2 (ru) | 2004-03-20 |
CN1187059C (zh) | 2005-02-02 |
US6660305B1 (en) | 2003-12-09 |
CN1316905A (zh) | 2001-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8383100B2 (en) | Method to treat and prevent skin diseases with Porifera-based therapeutic compositions treating and preventing skin diseases | |
BRPI0808065B1 (pt) | New cosmetic and / or pharmaceutical compositions and their applications | |
US20190358270A1 (en) | Porifera-based therapeutic compositions for treating and preventing skin diseases | |
CN110882207A (zh) | 一种用于皮肤修护的精华液制备工艺与方法 | |
JP6145505B2 (ja) | 光照射を用いた感光剤−ペプチドを有効成分として含む発毛改善または促進用組成物及びそれを用いた方法 | |
WO2000006180A1 (es) | Composicion para la estimulacion de la sintesis del pigmento melanico y procedimiento para su obtencion | |
ES2856498T3 (es) | Extracto de Daphne laureola y su uso para el tratamiento de dermopatías | |
KR101547758B1 (ko) | 탈모 예방 및 양모, 육모 촉진용 조성물 | |
CN107625956B (zh) | 一种木瓜蛋白酶组合物及其制备方法和应用 | |
ES2342436T3 (es) | Composicion para empleo cosmetico o farmaceutico-dermatologico. | |
ES2763341T3 (es) | Complejo proteomelánico bioasimilable, preparación y usos | |
CN112521389A (zh) | 用于促进伤口愈合的药物及方法 | |
EP1661565B1 (en) | Composition comprising l-proline for the treatment of vitiligo | |
CN115944571B (zh) | 一种促头发生长和修护发根的精华喷雾及其制备方法 | |
KR20040106865A (ko) | 항노화 효과가 있는 한약제 추출물 화장료 첨가조성물 | |
KR101369964B1 (ko) | 알로에, 흰목이버섯 및 복령 추출물을 함유하는 두피자극완화용 외용제조성물 | |
JPS5944317A (ja) | 白班治療組成物およびその製造法 | |
RU2118155C1 (ru) | Мазь для лечения заболеваний и повреждений кожи "галлодерм" | |
BR102015010848B1 (pt) | formulação fitoterápica contendo extrato de embaúba com atividade cicatrizante | |
MXPA06001351A (es) | Composicion para el tratamiento del vitiligo | |
MXPA06002744A (es) | Composicion terapeutica basada en porifera para tratar y prevenir enfermedades de la piel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99810745.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BG BR CA CN HU IN JP MX RU UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2336526 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/001014 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2000 562034 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00071/DE Country of ref document: IN Ref document number: IN/PCT/2001/00072/DE Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 1999 105208 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999934451 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09744633 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999934451 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999934451 Country of ref document: EP |